HENDERSON, NV / ACCESSWIRE / February 19, 2019 / Biotechnology is coming back strong in 2019 as the iShares Nasdaq Biotechnology Index's 16% surge higher during the first month and a half of this new year shows. There are several companies in the space we think are worth a look: BioRestorative Therapies, Inc. (BRTX) tops our list due to their potential in two huge markets. Their BRTX-100 has shown positive results in both preclinical animal and human studies as a non-opioid chronic lower back pain treatment and their "ThermoStem" treatment targets the obesity. BioRestorative has an open IND (Investigational New Drug) and has agreed with the FDA on a Phase 2 trial protocol that is targeted to start Q1 of 2019 (this quarter). Since there could be news any day, it'd be wise to start your research immediately.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), AcelRx Pharmaceuticals, Inc. (NYSE: ACRX), Conformis, Inc. (NASDAQ: CFMS), Cronos Group, Inc. (NASDAQ: CRON), and Zynerba Pharmaceuticals, Inc. (ZYNE).
The Global Chronic Low Back Pain Market is relied upon to achieve an estimation of US$ 9.19 billion by 2025, developing at a CAGR of 5.1% amid the forecast time frame of 2017-2025. BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.241M, Share Price: $0.70), a life sciences company focused on stem cell-based therapies as we mentioned above, is working on their BRTX-100 solution.
The company is also developing a therapy to fight the obesity epidemic. Their "ThermoStem" uses brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
_____
AcelRx Pharmaceuticals, Inc. (ACRX) (Market Cap: $221.541M, Share Price: $2.90) ended last year on a high note being added to the Nasdaq Biotechnology Index. Recently, the stock has been trending up.
_____
Conformis, Inc. (CFMS) (Market Cap: $82.267M, Share Price: $1.26), a medical technology company that uses its proprietary iFit Image-to-Implant technology, recently announced financial results for the fourth quarter. The company's total revenue of $22.0 million, up 6% year-over-year on a reported basis and 7% year-over-year on a constant currency basis.
_____
Cronos Group, Inc. (CRON) (Market Cap: $3.787B, Share Price: $21.29) continues to reach new highs since announcing in early December that it had entered into a subscription agreement with Altria Group, Inc., one of the leading tobacco brands in the world, pursuant to which Altria agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company.
_____
Zynerba Pharmaceuticals, Inc. (ZYNE) (Market Cap: $92.012M, Share Price: $5.22) released 12-month clinical data that describes the lifelong impact of ZYN002 on developmental and responsive symptoms of Fragile X syndrome. In a poster for the presentation in the 57th annual meeting, Professor Steven Siegel gives the presentation of the 12-month data of the second phase of the clinical trial of […] The post Zynerba Gives Clinical Update, Lifelong Impact of ZYN002 appeared first on Market Exclusive.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: Regal Consulting, LLC